BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,067 filers reported holding BAXTER INTL INC in Q2 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $294,000 | +13.5% | 3,364 | +6.6% | 0.00% | 0.0% |
| Q2 2019 | $259,000 | +0.8% | 3,157 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $257,000 | +23.6% | 3,157 | 0.0% | 0.00% | +50.0% |
| Q4 2018 | $208,000 | -14.4% | 3,157 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $243,000 | +4.3% | 3,157 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $233,000 | +13.7% | 3,157 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $205,000 | -25.7% | 3,157 | -26.0% | 0.00% | 0.0% |
| Q4 2017 | $276,000 | +6.6% | 4,264 | +3.2% | 0.00% | 0.0% |
| Q3 2017 | $259,000 | -6.8% | 4,130 | -10.2% | 0.00% | -33.3% |
| Q2 2017 | $278,000 | -99.7% | 4,600 | -99.7% | 0.00% | -99.7% |
| Q1 2015 | $101,493,000 | -30.8% | 1,481,652 | -25.9% | 0.91% | -29.0% |
| Q4 2014 | $146,593,000 | +139.7% | 2,000,175 | +134.8% | 1.28% | +72.5% |
| Q3 2014 | $61,148,000 | -58.9% | 851,994 | -58.6% | 0.74% | -42.2% |
| Q2 2014 | $148,814,000 | -3.6% | 2,058,279 | -1.9% | 1.28% | -2.4% |
| Q1 2014 | $154,349,000 | +5.2% | 2,097,709 | -0.5% | 1.32% | -2.2% |
| Q4 2013 | $146,676,000 | +14.5% | 2,108,927 | +8.1% | 1.34% | -10.6% |
| Q3 2013 | $128,098,000 | +6.2% | 1,950,043 | +12.0% | 1.50% | +1.3% |
| Q2 2013 | $120,654,000 | +2.0% | 1,741,796 | +6.9% | 1.48% | +0.8% |
| Q1 2013 | $118,312,000 | – | 1,628,744 | – | 1.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |